Amgen (AMGN) Tops Q2 EPS by 10c; Boosts FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
Go back to Amgen (AMGN) Tops Q2 EPS by 10c; Boosts FY16 Outlook
July 28, 2016 7:18 AM EDT
Leerink Partners reiterated a Market Perform rating on Amgen (NASDAQ: AMGN), and raised the price target to $201.00 (from $186.00), following the company's 2Q earnings report. AMGN reported total revenues of $5.69bn, beating consensus by 3%. The company also reported an operating margin of 51% on expenses of $2.876bn, which was in-line with consensus.
Analyst Geoffrey C. Porges commented, "Amgen Reported Q2 Results Beating Consensus for Revenue by 2% and Beating by 3% on EPS. Total revenue of $5.69bn included $5.474bn in product sales that beat consensus by 3% and missed our estimate by -2%. As with the... More
July 28, 2016 6:46 AM EDT
BMO Capital analyst M. Ian Somaiya reiterated an Outperform rating and raised his price target on Amgen (NASDAQ: AMGN) to $190.00 (from $186.00) following top and bottom line beat in Q2.
Somaiya commented, "We are raising our price target on the AMGN shares to $190... More
